We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
From Oct 2023 to Apr 2024
By Denny Jacob
Merck received approval from the Food and Drug Administration for cancer drug Keytruda in combination with chemoradiotherapy as a treatment for patients with FIGO 2014 Stage III-IVA cervical cancer.
The healthcare company said the approval marks the third indication for keytruda in cervical cancer and the 39th indication for keytruda in the United States.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 12, 2024 17:58 ET (22:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
